CytomX Therapeutics, Inc. (CTMX)
2.545
-0.02
(-0.59%)
USD |
NASDAQ |
Oct 07, 16:00
2.545
0.00 (0.00%)
After-Hours: 16:11
CytomX Therapeutics EPS Diluted (Quarterly) : -0.0944 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0944 |
| March 31, 2026 | -0.1029 |
| December 31, 2025 | -0.1734 |
| September 30, 2025 | -0.0862 |
| June 30, 2025 | -0.0012 |
| March 31, 2025 | 0.2699 |
| December 31, 2024 | 0.2357 |
| September 30, 2024 | 0.0673 |
| June 30, 2024 | -0.077 |
| March 31, 2024 | 0.1669 |
| December 31, 2023 | 0.0124 |
| September 30, 2023 | 0.0369 |
| June 30, 2023 | -0.0163 |
| March 31, 2023 | -0.05 |
| December 31, 2022 | -0.1325 |
| September 30, 2022 | -0.441 |
| June 30, 2022 | -0.369 |
| March 31, 2022 | -0.489 |
| December 31, 2021 | -0.4011 |
| September 30, 2021 | -0.3463 |
| June 30, 2021 | -0.2958 |
| March 31, 2021 | -0.2551 |
| December 31, 2020 | -0.3173 |
| Date | Value |
|---|---|
| September 30, 2020 | -0.3184 |
| June 30, 2020 | -0.3404 |
| March 31, 2020 | 0.2594 |
| December 31, 2019 | -0.78 |
| September 30, 2019 | -0.5218 |
| June 30, 2019 | -0.6387 |
| March 31, 2019 | -0.313 |
| December 31, 2018 | -0.715 |
| September 30, 2018 | -0.5335 |
| June 30, 2018 | -0.35 |
| March 31, 2018 | -0.40 |
| December 31, 2017 | 0.0161 |
| September 30, 2017 | -0.2773 |
| June 30, 2017 | -0.69 |
| March 31, 2017 | -0.23 |
| December 31, 2016 | -0.3846 |
| September 30, 2016 | -0.40 |
| June 30, 2016 | -0.39 |
| March 31, 2016 | -0.44 |
| December 31, 2015 | -0.3343 |
| September 30, 2015 | -14.26 |
| June 30, 2015 | -0.12 |
| March 31, 2015 | -0.2128 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 12.23 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -20.67M |
| Revenue (Quarterly) | 1.418M |
| Total Expenses (Quarterly) | 22.08M |
| Enterprise Value | 232.33M |
| Gross Profit Margin (Quarterly) | 96.69% |
| Profit Margin (Quarterly) | -1.46K% |
| Earnings Yield | -17.95% |
| Normalized Earnings Yield | -17.97 |